New developments in the treatment of metastatic gastric cancer: Focus on trastuzumab

Jeffrey S. Rose, Tanios S. Bekaii-Saab

Research output: Contribution to journalReview article

15 Scopus citations

Abstract

Patients with metastatic gastric cancer have a poor outcome. The development of new combinations of chemotherapy has led to steady but only modest gains in overall survival with largest effects reported with two- and three-drug regimens. Trastuzumab, a fully humanized monoclonal antibody directed at the human epidermal growth factor receptor-2 (HER2), has been found to improve response rate and survival in patients with advanced gastric cancer. This update will review the role of HER2 and summarize therapeutic advances in the use of trastuzumab in advanced gastric cancer.

Original languageEnglish (US)
Pages (from-to)21-26
Number of pages6
JournalOncoTargets and Therapy
Volume4
DOIs
StatePublished - 2011

Keywords

  • Adenocarcinoma
  • Chemotherapy
  • Gastric
  • Gastroesophageal
  • Trastuzumab

ASJC Scopus subject areas

  • Oncology
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'New developments in the treatment of metastatic gastric cancer: Focus on trastuzumab'. Together they form a unique fingerprint.

  • Cite this